Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment

International Review of Psychiatry

Volumn 25, Issue 5, 2013, Pages 572-578

  Frieling, Helge ^a   Tadić, André ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HISTONE DEACETYLASE INHIBITOR; IMIPRAMINE; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ARTICLE; EPIGENETICS; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAJOR DEPRESSION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; EPIGENOMICS; GENETIC TESTING; HUMANS; PHARMACOGENETICS;

EID: 84886703354     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.816657     Document Type: Article

References (43)

1. Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., ? Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet, 373, 746-758.
2. Devlin, A.M., Brain, U., Austin, J. & Oberlander, T.F. (2010). Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS ONE, 5, e12201.
3. Domschke, K., Tidow, N., Kuithan, H., Schwarte, K., Klauke, B., Ambree, O., ? Deckert, J. (2012). Monoamine oxidase A gene DNA hypomethylation-A risk factor for panic disorder? International Journal of Neuropsychopharmacology, 15, 1217-1228.
4. Dreim ü ller, N., Tadi ć, A., Dragicevic, A., Boland, K., Bondy, B., Lieb, K., ? Hiemke, C. (2012). The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry, 45, 108-113.
5. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2007). Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 9, 819-825.
6. Fernandes, B.S., Gama, C.S., Cereser, K.M., Yatham, L.N., Fries, G.R., Colpo, G., ? Kapczinski, F. (2011). Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 45, 995-1004.
7. Fuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., ? Terao, T. (2011). DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS ONE, 6, e23881.
8. Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., ? Hamilton, S.P. (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry, 67, 133-138.
9. GENDEP Investigators, MARS Investigators & STAR D Investigators . (2013). Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. American Journal of Psychiatry, 170, 207-217.
10. Hughes, B. (2009). Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nature Reviews Drug Discovery, 8, 523-524.
11. Ising, M., Lucae, S., Binder, E.B., Bettecken, T., Uhr, M., Ripke, S., ? M ü ller-Myhsok, B. (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry , 66, 966-975.
12. Kang, H.J., Kim, J.M., Stewart, R., Kim, S.Y., Bae, K.Y., Kim, S.W., ? Yoon, J.S. (2013). Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Progress in Neuropsychopharmacology and Biological Psychiatry, 44, 23-28.
13. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L., Licinio, J., Roots, I. & Brockm ö ller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9, 442-473.
14. Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J.C., Pariante, C.M., ? Binder, E.B. (2013). Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nature Neuroscience, 16, 33-41.
15. Laje, G. & McMahon, F.J. (2011). Genome-wide association studies of antidepressant outcome: A brief review. Progress of Neuropsychopharmacology and Biological Psychiatry, 35, 1553-1557.
16. Licinio, J. & Wong, M.L. (2011). Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience, 13, 63-71.
17. Lopez, J.P., Mamdani, F., Labonte, B., Beaulieu, M.M., Yang, J.P., Berlim, M.T., ? Turecki, G. (2013). Epigenetic regulation of BDNF expression according to antidepressant response. Molecular Psychiatry, 18, 398-399.
18. Melas, P.A., Rogdaki, M., Lennartsson, A., Bjork, K., Qi, H., Witasp, A., ? Lavebratt, C. (2012). Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. International Journal of Neuropsychopharmacology, 15, 669-679.
19. Melas, P.A., Wei, Y., Wong, C.C., Sj ö holm, L.K., Aberg, E., Mill, J., ? Lavebratt, C. (2013). Genetic and epigenetic associations of MAOA and NR3C1 with depression and childhood adversities. International Journal of Neuropsychopharmacology, 16, 1513-1528.
20. Murgatroyd, C., Patchev, A.V., Wu, Y., Micale, V., Bockmuhl, Y., Fischer, D., ? Spengler, D. (2009). Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nature Neuroscience, 12, 1559-1566.
21. Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., ? Memish, Z.A. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2197-2223.
22. Narasimhan, S. & Lohoff, F.W. (2012). Pharmacogenetics of antidepressant drugs: Current clinical practice and future directions . Pharmacogenomics, 13, 441-464.
23. Oberlander, T.F., Weinberg, J., Papsdorf, M., Grunau, R., Misri, S. & Devlin, A.M. (2008). Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics, 3, 97-106.
24. Olgiati, P., Bajo, E., Bigelli, M., De Ronchi, D. & Serretti, A. (2012). Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high-and middle-income European countries. Progress in Neuropsychopharmacology and Biological Psychiatry, 36, 147-154.
25. Perlis, R.H., Patrick, A., Smoller, J.W. & Wang, P.S. (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR D study. Neuropsychopharmacology, 34, 2227-2236.
26. Perroud, N., Bondolfi, G., Uher, R., Gex-Fabry, M., Aubry, J.M., Bertschy, G., ? Kosel, M. (2011). Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 12, 365-377.
27. Rodenhiser, D. & Mann, M. (2006). Epigenetics and human disease: Translating basic biology into clinical applications. Canadian Medical Association Journal, 174, 341-348.
28. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., ? Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR D report. American Journal of Psychiatry, 163, 1905-1917.
29. Schroeder, M., Hillemacher, T., Bleich, S. & Frieling, H. (2012). The epigenetic code in depression: Implications for treatment. Clinical Pharmacology and Therapeutics, 91, 310-314.
30. Tadi ć, A., Mü ller-Engling, L., Schlicht, K.F., Kotsiari, A., Dreim ü ller, N., Kleimann, A., ? Frieling, H. (2013). Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Molecular Psychiatry, doi: 10.1038/mp.2013.58
31. Tadi ć, A., Wagner, S., Schlicht, K.F., Peetz, D., Borysenko, L., Dreimuller, N., ? Lieb, K. (2011). The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry, 35, 415-420.
32. Tansey, K.E., Guipponi, M., Perroud, N., Bondolfi, G., Domenici, E., Evans, D., ? Uher, R. (2012). Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: A genome-wide analysis of individual-level data and a meta-analysis. PLoS Medicine, 9, e1001326.
33. Thomas, L., Mulligan, J., Mason, V., Tallon, D., Wiles, N., Cowen, P., ? Lewis, G. (2008). Genetic and clinical predictors of treatment response in depression: The GenPod randomized trial protocol. Trial, 9, 29.
34. Thomas, R.P., Recht, L. & Nagpal, S. (2013). Advances in the management of glioblastoma: The role of temozolomide and MGMT testing. Clinical Pharmacology, 5, 1-9.
35. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., ? STAR D Study Team. (2006). Evaluation of outcomes with citalopram for depression using measurement based care in STAR D: Implications for clinical practice. American Journal of Psychiatry 2006, 163, 28-40.
36. Uddin, M., Koenen, K.C., Aiello, A.E., Wildman, D.E., de los Santos, R. & Galea, S. (2011). Epigenetic and inflammatory marker profiles associated with depression in a communitybased epidemiologic sample. Psychological Medicine, 41, 997-1007.
37. Uher, R., Perroud, N., Ng, M.Y., Hauser, J., Henigsberg, N., Maier, W., ? McGuffin, P. (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry, 167, 555-564.
38. Unternaehrer, E., Luers, P., Mill, J., Dempster, E., Meyer, A.H., Staehli, S., ? Meinlschmidt, G. (2012). Dynamic changes in DNA methylation of stress-associated genes (OXTR, BDNF) after acute psychosocial stress. Translational Psychiatry, 2, e150.
39. van Ijzendoorn, M.H., Caspers, K., Bakermans-Kranenburg, M.J., Beach, S.R.H. & Philibert, R. (2010). Methylation matters: Interaction between methylation density and serotonin transporter genotype predicts unresolved loss or trauma. Biological Psychiatry, 68, 405-407.
40. Wang, D., Szyf, M., Benkelfat, C., Provencal, N., Turecki, G., Caramaschi, D., ? Booij, L. (2012). Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. PLoS ONE, 7, e39501.
41. Weaver, I.C.G., Cervoni, N., Champagne, F.A., D'Alessio, A.C., Sharma, S., Seckl, J.R., ? Meaney, M.J. (2004). Epigenetic programming by maternal behavior. Nature Neuroscience, 7, 847-854.
42. Weizman, S., Gonda, X., Dome, P. & Faludi, G. (2012). Pharmacogenetics of antidepressive drugs: A way towards personalized treatment of major depressive disorder. Neuropsychopharmacologia Hungarica, 14, 87-101.
43. Wiedemann, K. (2011). Biomarkers in development of psychotropic drugs. Dialogues in Clinical Neuroscience, 13, 225-234.